TERN News

Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Terns Announces Pricing of Upsized $650 Million Public Offering

Terns Announces Proposed Public Offering

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

TERN, A Winner of the U.S. Army's Highly Competitive xTechOverwatch Program, Selected from a Field of Hundreds to Accelerate Autonomous Capabilities